Currently, the first prospective clinical trial (National Clinical Trial number (NCT) at Clinicaltrals.gov: NCT06059014) titled Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients with Metastatic Clear Cell Renal Cancer (PRadR) has begun enrollment and is expected to provide data on the safety and efficacy of RLT with [177Lu]Lu-PSMA-1 in ccRCC. Here, FOLH1 is linked to clear cell renal carcinoma.